Michael L Maitland

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. doi request reprint Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer
    Michael L Maitland
    University of Chicago, Section of Hematology Oncology, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    BMC Cancer 14:5. 2014
  2. pmc Estimation of renal cell carcinoma treatment effects from disease progression modeling
    M L Maitland
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Clin Pharmacol Ther 93:345-51. 2013
  3. pmc Volumes to learn: advancing therapeutics with innovative computed tomography image data analysis
    Michael L Maitland
    The University of Chicago Medical Center, Chicago, Department of Medicine, Section of Hematology Oncology, Committee on Clinical Pharmacology and Pharmacogenomics, MC2115, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Clin Cancer Res 16:4493-5. 2010
  4. pmc Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors
    Michael L Maitland
    Department of Medicine, University of Chicago Medical Center, 5841Chicago, IL 60637, USA
    J Natl Cancer Inst 102:596-604. 2010
  5. pmc Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment
    Michael L Maitland
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 15:6250-7. 2009
  6. ncbi request reprint Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer
    Michael L Maitland
    Section of Hematology Oncology, The Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637, USA
    Lung Cancer 54:243-5. 2006
  7. pmc Resampling phase III data to assess phase II trial designs and endpoints
    Manish R Sharma
    Departments of Medicine and Health Studies, University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 18:2309-15. 2012
  8. pmc Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies
    Tara C Gangadhar
    Division of Hematology and Oncology, University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 17:1956-63. 2011
  9. pmc Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients
    Manish R Sharma
    Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 19:3059-67. 2013
  10. pmc Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors
    Kelly L Snider
    Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
    Target Oncol 4:67-76. 2009

Research Grants

Detail Information

Publications28

  1. doi request reprint Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer
    Michael L Maitland
    University of Chicago, Section of Hematology Oncology, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    BMC Cancer 14:5. 2014
    ..In a phase II trial that was closed to accrual because of changes in clinical practice we examined the relationships among candidate biomarkers, quantitative changes in tumor size, progression-free and overall survival...
  2. pmc Estimation of renal cell carcinoma treatment effects from disease progression modeling
    M L Maitland
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Clin Pharmacol Ther 93:345-51. 2013
    ..1) with 50 patients per arm. Model-based quantitation of treatment effect with computed tomography (CT) imaging offers a scaffold on which to develop new, more efficient, phase II trial end points and analytic strategies for RCC...
  3. pmc Volumes to learn: advancing therapeutics with innovative computed tomography image data analysis
    Michael L Maitland
    The University of Chicago Medical Center, Chicago, Department of Medicine, Section of Hematology Oncology, Committee on Clinical Pharmacology and Pharmacogenomics, MC2115, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Clin Cancer Res 16:4493-5. 2010
    ..Volumetric measurements, relying on already widely available standard clinical imaging techniques, could shorten the observation intervals needed to identify cohorts of patients sensitive or resistant to treatment...
  4. pmc Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors
    Michael L Maitland
    Department of Medicine, University of Chicago Medical Center, 5841Chicago, IL 60637, USA
    J Natl Cancer Inst 102:596-604. 2010
    ..Proper agent selection, dosing, and scheduling of follow-up should enable maintaining VSP inhibition while avoiding the complications associated with excessive or prolonged elevation in BP...
  5. pmc Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment
    Michael L Maitland
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 15:6250-7. 2009
    ..This prospective, single-center, cohort study characterized ambulatory blood pressure monitoring as an early pharmacodynamic biomarker of VEGF signaling pathway inhibition by sorafenib...
  6. ncbi request reprint Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer
    Michael L Maitland
    Section of Hematology Oncology, The Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637, USA
    Lung Cancer 54:243-5. 2006
    ..The frequency with which camptothecin-related dyspnea is associated with diffuse alveolar damage might be underestimated and is of special concern in patients with limited pulmonary reserve...
  7. pmc Resampling phase III data to assess phase II trial designs and endpoints
    Manish R Sharma
    Departments of Medicine and Health Studies, University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 18:2309-15. 2012
    ..placebo; TARGET) and a negative (AE941 vs. placebo) phase III trial in metastatic renal cancer to compare the ability of various designs and endpoints to predict the known results...
  8. pmc Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies
    Tara C Gangadhar
    Division of Hematology and Oncology, University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 17:1956-63. 2011
    ..Sorafenib and sunitinib are small molecule inhibitors of multiple kinases including VEGF receptor (VEGFR) kinases. These agents have different mechanisms of action, providing a strong rationale for combination...
  9. pmc Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients
    Manish R Sharma
    Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 19:3059-67. 2013
    ..We conducted a pharmacokinetic study of vismodegib in patients with advanced solid tumors to explore the effects of food on drug exposure...
  10. pmc Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors
    Kelly L Snider
    Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
    Target Oncol 4:67-76. 2009
    ..In addition to reviewing current concepts for the cardiovascular toxicities of angiogenesis inhibitors, we discuss how better understanding the pharmacologic basis for these effects could optimize their use for individual patients...
  11. doi request reprint Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth
    Nisha C Kakodkar
    Departments of Pediatrics, University of Chicago, Chicago, IL 60637, USA
    Pediatr Blood Cancer 59:642-7. 2012
    ..In this study we tested the effects of sorafenib, a multi-kinase inhibitor, on neuroblastoma cell proliferation and signaling, and in mice with subcutaneous human neuroblastoma xenografts or orthotopic adrenal tumors...
  12. pmc Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension
    Liliana Moreno-Vinasco
    Section of Pulmonary and Critical Care Medicine, Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Physiol Genomics 33:278-91. 2008
    ..In summary, sorafenib represents a novel potential treatment for severe PH with the MAPK cascade a potential canonical target...
  13. doi request reprint Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients
    Ezra E W Cohen
    Departments of Medicine, University of Chicago, Chicago, IL 60637, USA
    Clin Cancer Res 18:4785-93. 2012
    ..Nevertheless, sirolimus is readily available, has been well studied in organ transplant patients, and shows efficacy in several preclinical cancer models...
  14. doi request reprint Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity
    Rajesh Gupta
    Division of Cardiology and Feinberg Cardiovascular Research Institute, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA
    Curr Hypertens Rep 13:430-5. 2011
    ..The associated heart failure is less common; it can be reversible but must be actively monitored and managed. Mechanistic insights suggest that an attentive clinical strategy for hypertension could prevent severe cardiotoxicity...
  15. pmc Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis
    Sumita S Bhatta
    Department of Medicine, Section of Hematology Oncology, Chicago, IL 60637, USA
    Oncologist 18:965-70. 2013
    ..The effects of these changes are subtle at physiologic doses and are unlikely to be clinically useful biomarkers for guiding the administration of or predicting treatment responses to VEGF pathway inhibitors. ..
  16. pmc Cancer pharmacogenomics: strategies and challenges
    Heather E Wheeler
    Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, 900 East 57th Street, Chicago, Illinois 60637, USA
    Nat Rev Genet 14:23-34. 2013
    ..We discuss the application of germline genetics analysis methods to cancer pharmacogenomics with a focus on the special considerations for study design...
  17. ncbi request reprint Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer
    Theodore G Karrison
    Department of Health Studies, University of Chicago, Chicago, IL 60637, USA
    J Natl Cancer Inst 99:1455-61. 2007
    ..This design may efficiently eliminate truly ineffective therapy but may not reliably indicate whether subsequent phase III testing is warranted...
  18. doi request reprint Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science
    M Eileen Dolan
    Committee on Clinical Pharmacology and Pharmacogenomics, 900 E 57th Street, KCBD 7100, University of Chicago, Chicago, IL 60637, USA
    Pharmacogenomics 14:1383-7. 2013
    ..The mission of the Center is to facilitate research, education and implementation of pharmacogenomics to realize the true potential of personalized medicine and improve the lives of patients. ..
  19. pmc Clinical trials in the era of personalized oncology
    Michael L Maitland
    Section of Hematology Oncology, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, IL 60637, USA
    CA Cancer J Clin 61:365-81. 2011
    ....
  20. pmc Analysis of the yield of phase II combination therapy trials in medical oncology
    Michael L Maitland
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 16:5296-302. 2010
    ..We hypothesized that recognized flaws of single-arm trials could be magnified in combination treatment studies, leading to many reported positive phase II trials but with a low fraction resulting in practice-changing phase III trials...
  21. doi request reprint RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point
    Manish R Sharma
    Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cancer Res 72:5145-9; discussion 5150. 2012
    ..We discuss how the new paradigm overcomes these limitations and provides a framework for answering the key questions of the oncologist and improving patient outcomes...
  22. ncbi request reprint TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
    Michael L Maitland
    Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, and Cancer Research Center, University of Chicago, Chicago, IL 60637, USA
    Trends Pharmacol Sci 27:432-7. 2006
    ....
  23. doi request reprint Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies
    Manish R Sharma
    Section of Hematology, University of Chicago Medical Center, Chicago, IL, USA
    Cancer J 15:426-30. 2009
    ..Finally, we make the case that randomized phase II trials are feasible, as long as reasonable statistical standards are applied...
  24. doi request reprint Inflammation, growth factors, and pulmonary vascular remodeling
    Paul M Hassoun
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, Maryland 21287, USA
    J Am Coll Cardiol 54:S10-9. 2009
    ....
  25. ncbi request reprint Interpreting disparate responses to cancer therapy: the role of human population genetics
    Michael L Maitland
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
    J Clin Oncol 24:2151-7. 2006
    ..Understanding these principles will help investigators better design clinical trials to identify the variables most relevant to subsequent individualization of a cancer therapy...
  26. ncbi request reprint Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer
    Stephen L Archer
    University of Chicago, Section of Cardiology, IL 60637, USA
    Am J Physiol Heart Circ Physiol 294:H570-8. 2008
    ..Mitochondrial abnormalities that disturb the ROS-HIF-1alpha-Kv1.5 O(2)-sensing pathway contribute to the pathogenesis of PAH and cancer and constitute promising therapeutic targets...
  27. pmc Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data
    Xinan Yang
    Center for Biomedical Informatics, The University of Chicago, Chicago, IL, USA
    J Biomed Inform 43:376-84. 2010
    ..The purpose of this study was to develop a bioinformatics-based method to predict specific adverse events (AEs) in humans associated with the inhibition of particular kinase targets (KTs)...
  28. ncbi request reprint Terminal ballistics of kinase inhibitors: there are no magic bullets
    Michael L Maitland
    Ann Intern Med 145:702-3. 2006

Research Grants2

  1. Translational Medicine and Cancer Therapy with Vasculature-Targeted Agents
    Michael Maitland; Fiscal Year: 2007
    ..This "personalized medicine" promises safer, more effective treatment for patients with cancer. This grant will help train Dr. Maitland to be an expert in the conduct of clinical and laboratory studies for personalized cancer medicine. ..